TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
34 hedge funds and large institutions have $48.1M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 4 closing their positions.
61% more capital invested
Capital invested by funds: $29.8M → $48.1M (+$18.3M)
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 33 → 34 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.29M |
| 2 |
PCM
Puissance Capital Management
New York
|
+$3.29M |
| 3 |
TI
Telemetry Investments
New York
|
+$1.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 5 |
Renaissance Technologies
New York
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$184K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$178K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$105K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$86K |
| 5 |
VF
Virtu Financial
New York
|
-$61.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QF
26
QVT Financial
New York
| $63K | -$59.6K | -112 | -49% |
|
|
WA
27
Waverly Advisors
Birmingham,
Alabama
| $58K | – | – | – |
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $53K | -$9.57K | -18 | -15% |
|
|
VF
29
Virtu Financial
New York
| $50K | -$61.2K | -115 | -55% |
|
30
UBS Group
Zurich,
Switzerland
| $38K | +$23.9K | +45 | +173% |
|
|
TSS
31
Two Sigma Securities
New York
| $27K | +$27.1K | +51 | New |
|
32
Acadian Asset Management
Boston,
Massachusetts
| $16K | -$1.06K | -2 | -6% |
|
|
PAM
33
Panagora Asset Management
Boston,
Massachusetts
| $11K | +$10.6K | +20 | New |
|
34
Wells Fargo
San Francisco,
California
| $3K | -$532 | -1 | -14% |
|
|
35
Russell Investments Group
London,
United Kingdom
| – | -$105K | -229 | Closed |
|
|
36
Ameriprise
Minneapolis,
Minnesota
| – | -$86K | -186 | Closed |
|
|
PAG
37
Private Advisor Group
Morristown,
New Jersey
| – | -$23K | -50 | Closed |
|
|
PWM
38
Perigon Wealth Management
San Francisco,
California
| – | -$1K | -2 | Closed |
|
TCON Hedge Fund Activity: Q2 2018 in Review
34 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2018, worth a combined $48.1M — up 61% from $29.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TCON positions and 4 closed out — a net gain of 1 holder — while 14 added to existing stakes and 10 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $3.29M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $184K.
- 34 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2018, up from 33 in Q1 2018.
- Funds reported $48.1M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2018, up 61% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 4 closed out, a net change of +1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was 683 Capital Management, an estimated $3.29M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Jacobs Levy Equity Management, an estimated $184K sold.
Based on aggregated 13F filings for Q2 2018.